Beaird Harris Wealth Management LLC Purchases New Position in Twist Bioscience Co. (NASDAQ:TWST)

Beaird Harris Wealth Management LLC acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,100 shares of the company’s stock, valued at approximately $95,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Caprock Group LLC lifted its holdings in Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares during the last quarter. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. Arizona State Retirement System lifted its stake in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after buying an additional 308 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after buying an additional 312 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after buying an additional 363 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TWST shares. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday. They issued an “outperform” rating and a $60.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Price Performance

Shares of TWST stock opened at $47.50 on Friday. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The stock has a fifty day moving average price of $44.94 and a 200 day moving average price of $46.63. The stock has a market cap of $2.82 billion, a P/E ratio of -13.19 and a beta of 1.82.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,216 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the completion of the transaction, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. This represents a 0.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 3,310 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $143,025.10. Following the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at approximately $3,654,917.85. The trade was a 3.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 101,787 shares of company stock valued at $4,584,508. Company insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.